News
MCL: Event-free survival at 2 years bodes well
With current therapies, patients who achieve 24 months of event-free survival live almost as long as the general population.
News
CLL phase 3 study: Zanubrutinib bests ibrutinib
The second-generation Bruton’s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study.
News
Transplant provides no clear survival benefit in real-world MCL study
The findings apparently contradict the survival benefit seen in clinical trial data, authors said, but are consistent with other recent...
News
Blame MCL, not transplantation, for late effects?
In patients with mantle cell lymphoma, long-term complications appeared to be caused by the disease itself, not by intensive therapy.
News
Phase 3 trial yields better way to predict MCL outcomes
In a phase 3 trial of mantle cell lymphoma outcomes, repeated evaluations of minimal residual disease over time improved prognostic power.
News
Telemedicine helps SCD patients survive COVID, but more need access
The second COVID-19 wave brought zero deaths and fewer complicated hospitalizations at the largest U.S. adult sickle cell disease center, but care...
News
Life-threatening paradoxical bronchospasm may escape recognition in patients with COPD or asthma
Greater recognition and more education is needed, according to an investigator who conducted a study of spirometry tests at a VA medical center....
News
9-step ladder may kids with allergies return to eggs
Attempts to reintroduce egg into the child’s diet can start at the age of 12 months or 6 months from the last reaction.
News
Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
In an observational registry-based study, dropping the 110-bpm heart rate threshold improved sensitivity for low-risk PE, while increasing it...